Loading
A phase 1/2 trial of balstilimab and cyclophosphamide in pancreatic cancer, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, now recruiting.
Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer is a phase 1/2, interventional study registered as NCT06782932 by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, with a registry enrolment figure of 38 participants, started 2025-05-27 and due to reach its primary completion in 2028-12. Interventions recorded: AGEN2373; Balstilimab; Cyclophosphamide; GVAX; AGEN2373 (RP2D); Balstilimab; mKRASvax. Conditions listed: Pancreatic Cancer. Primary outcome: Dose Limiting Toxicities in Phase I participants; Number of participants experiencing Grade 3 or Higher study drug-related toxicities; Number of participants who form Intratumoral tertiary lymphoid structures (TLS). Pancreatic eligibility wording from the registry: "* Have a newly diagnosed, biopsy-proven adenocarcinoma of the pancreas". Sites: United States. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Resectable pancreatic ductal adenocarcinoma, Cyclophosphamide, Pancreatic cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/